Q3 Earnings Estimate for Immatics Issued By Leerink Partnrs

Key Points

• Leerink Partners has downgraded its Q3 2025 earnings estimate for Immatics N.V. to a loss of ($0.50) per share, a decrease from the previous estimate of ($0.41).
• The consensus target price for Immatics currently stands at $14.67, with a rating of "Moderate Buy" from analysts; however, it includes mixed recommendations such as one sell, four buy, and one strong buy ratings.
• Immatics reported a loss of ($0.66) EPS in its latest quarterly earnings, missing the consensus estimate by ($0.28), with actual revenues of $6.48 million significantly below expectations of $13.05 million.

Immatics N.V. (NASDAQ:IMTX - Free Report) - Investment analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of Immatics in a report released on Wednesday, August 13th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per share of ($0.50) for the quarter, down from their previous estimate of ($0.41). The consensus estimate for Immatics' current full-year earnings is ($0.72) per share. Leerink Partnrs also issued estimates for Immatics' Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.12) EPS and FY2026 earnings at ($1.81) EPS.

Several other equities research analysts have also recently commented on the stock. Wall Street Zen cut shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Zacks Research cut shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immatics in a research report on Wednesday, May 28th. They set a "buy" rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $14.67.

Immatics Trading Up 1.5%

Shares of NASDAQ:IMTX traded up $0.0860 during trading on Monday, hitting $5.7160. 46,550 shares of the company's stock were exchanged, compared to its average volume of 757,879. Immatics has a 1-year low of $3.30 and a 1-year high of $13.09. The firm has a 50-day moving average price of $6.01 and a two-hundred day moving average price of $5.21. The firm has a market cap of $694.78 million, a P/E ratio of -8.78 and a beta of 0.93.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.28). Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%.The business had revenue of $6.48 million for the quarter, compared to analyst estimates of $13.05 million.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after buying an additional 2,231 shares in the last quarter. Vontobel Holding Ltd. bought a new position in Immatics in the second quarter valued at approximately $59,000. Virtus ETF Advisers LLC lifted its stake in Immatics by 34.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock valued at $68,000 after buying an additional 2,479 shares in the last quarter. Intellectus Partners LLC bought a new position in Immatics in the first quarter valued at approximately $70,000. Finally, Guggenheim Capital LLC bought a new position in Immatics in the fourth quarter valued at approximately $101,000. Institutional investors and hedge funds own 64.41% of the company's stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.